Study guide

4.4 Acute GVHD Prophylaxis, First-Line Steroids & Steroid-Refractory Therapy

Transplantation and Cellular Therapy Certified Nurse TCTCN

Track your progress as you read

Finished sections get a check mark.

1 Introduction & Exam Overview

1.1 The TCTCN Credential: Rename, Scope & Official Test Blueprint 1.2 TCTCN Eligibility, Test-Day Logistics, Scoring & Renewal 1.3 Building the Study Plan & Clinical Prioritization Framework 1.4 Clinical Triage Rehearsal & Exam-Day Question Strategy

2 Chapter 2: Foundations of Transplantation & Cellular Biology

2.1 Hematopoietic Lineage, the MHC & HLA Class I vs Class II Biology 2.2 HLA Typing Resolution, Donor Matching, DSA & ABO Compatibility 2.3 Disease Indications & the Cellular Therapy Modality Map 2.4 Pre-Transplant Risk Stratification & Organ Suitability Assessment 2.5 Stem Cell & Cellular Product Sources: Donor Selection Hierarchy 2.6 Conditioning Regimens & Lymphodepletion Principles 2.7 Recipient and Caregiver Education Across the Continuum

3 Chapter 3: Product Collection, Processing & Infusion Procedures

3.1 Stem Cell Mobilization: Niche Biology, Agents & CD34+ Collection Targets 3.2 Apheresis Nursing Care: Vascular Access, Citrate Toxicity & Donor Safety 3.3 Graft Engineering, ABO-Directed Processing & Cryopreservation Science 3.4 DMSO Toxicity, Premedication & Time-Critical Thawed Product Administration 3.5 Pre-Administration Verification, Equipment & CAR T Infusion Readiness 3.6 Infusion Monitoring & Acute Reaction Differential Management 3.7 Engraftment Definitions, Kinetics & Factors Impairing Recovery 3.8 Graft Failure Classification & Donor Chimerism Tracking

4 Chapter 4: Acute Post-HSCT Complications & Graft-versus-Host Disease

4.1 Acute GVHD: Billingham's Postulates, Classification & the Ferrara 3-Phase Model 4.2 Acute GVHD Organ Manifestations, Histopathology & MAGIC Staging 4.3 MAGIC Overall Grading & Acute GVHD Plasma Biomarkers 4.4 Acute GVHD Prophylaxis, First-Line Steroids & Steroid-Refractory Therapy 4.5 SOS/VOD: Microvascular Pathophysiology & Risk Stratification 4.6 SOS/VOD Diagnostic Criteria, Surveillance & Defibrotide Therapy 4.7 TA-TMA: Complement Pathophysiology, Harmonized Criteria & Differential 4.8 TA-TMA Management, Complement-Directed Therapy & Other Endothelial Syndromes

5 Chapter 5: Post-Transplant Infections & Supportive Care

5.1 Neutropenic Fever, Pre-Engraftment Phase & Empiric Antimicrobial Therapy 5.2 CMV: Risk Stratification, Letermovir Prophylaxis & DNAemia Treatment 5.3 EBV/PTLD, HHV-6 Encephalitis, BK Cystitis, Adenovirus, HSV & VZV 5.4 Invasive Fungal Infections (Aspergillus, Candida, Mucor) & PJP Prophylaxis 5.5 Supportive Care in Aplasia: Transfusion Guidelines, Oral Mucositis & Nutrition

6 Chapter 6: Post-Cellular Therapy Management, CRS & ICANS

6.1 CAR Structural Architecture, Generations & Costimulatory Domain Biology 6.2 The Vein-to-Vein Lifecycle, In Vivo Kinetics & On-Target B-Cell Aplasia 6.3 CRS Pathophysiology, Clinical Kinetics & Inflammatory Biomarkers 6.4 ASTCT CRS Grading, Tocilizumab & Escalation Management 6.5 ICANS: Assessment, ICE Scoring & Clinical Management 6.6 Delayed Cellular Toxicities: Prolonged Cytopenias, B-Cell Aplasia & IEC-HS 6.7 Symptom Management and Functional Recovery After Cellular Therapy

7 Chapter 7: Chronic GVHD & Long-Term Survivorship

7.1 Chronic GVHD: Three-Phase Immunobiology & NIH Classification 7.2 Chronic GVHD Diagnostic Manifestations, BOS & NIH Global Severity Scoring 7.3 Chronic GVHD: Systemic, Steroid-Sparing & Multidisciplinary Therapy 7.4 Late Effects: Endocrine, Cardiovascular, Bone Health & Secondary Malignancies 7.5 Immune Reconstitution & the Inactivated Re-Vaccination Schedule 7.6 Live Vaccines, Household Contact Precautions & Survivorship Care Plans 7.7 Post-HSCT Relapse: Surveillance, Immunologic Manipulation & Treatment

8 Chapter 8: Quality of Life, Ethics & Professional Practice Standards

8.1 Psychosocial Trajectories, Distress Screening & Delirium Assessment 8.2 Caregiver Planning, Financial & Cultural Navigation, and Sexual Health 8.3 Palliative Care Integration, Advance Directives & Ethical Considerations 8.4 FACT-JACIE Quality Standards, CIBMTR / NMDP Reporting & Compliance 8.5 Evidence-Based Practice, Discharge Education & Quality Improvement

4.4 Acute GVHD Prophylaxis, First-Line Steroids & Steroid-Refractory Therapy

Key Takeaways Explain This Topic AI

Acute GVHD prophylaxis is platform-specific. Common components include a calcineurin inhibitor with methotrexate or MMF, post-transplant cyclophosphamide-based regimens, serotherapy, or abatacept; timing, doses, trough goals and taper come from the transplant protocol.

Post-transplant cyclophosphamide targets proliferating alloreactive cells, but its schedule, uroprotection, fluids and accompanying immunosuppression require protocol verification and patient-specific monitoring.

Clinically significant acute GVHD commonly receives systemic corticosteroids, with dose and route based on organ involvement and severity; document organ response and reassess infection and treatment toxicity.

For steroid-refractory acute GVHD in patients age 12 years and older, the current U.S. ruxolitinib label starts 5 mg twice daily and permits consideration of 10 mg twice daily after at least 3 days if blood counts have not fallen by 50% or more; verify the current label, interactions and counts.

Last updated: September 2026

1. Acute GVHD Prophylaxis Strategies

Prophylaxis applies to allogeneic HCT, but there is no single regimen for every donor, graft source, conditioning platform, disease, or center. Common platforms combine tacrolimus or cyclosporine with short-course methotrexate or mycophenolate; others incorporate post-transplant cyclophosphamide (PTCy), antithymocyte globulin, sirolimus, or abatacept. Cord-blood, haploidentical, matched-unrelated, and matched-related protocols may differ.

Calcineurin inhibitors suppress IL-2 transcription through calcineurin/NFAT signaling. Monitor renal function, blood pressure, potassium, magnesium, glucose, neurologic symptoms, interacting CYP3A drugs, and protocol-defined whole-blood troughs. Trough targets and taper schedules are regimen- and assay-specific; a value cannot be interpreted without the current protocol and timing of the last dose.

PTCy is given after graft infusion in selected regimens to reduce proliferating alloreactive T cells while preserving stem-cell recovery and immune regulation. Days +3 and +4 with subsequent immunosuppression are common, but dose, schedule, fluid plan, mesna, and when accompanying agents start are protocol-specific. Assess urine output, fluid balance, hematuria, cardiac risk, nausea, and cytopenias. Verify the exact regimen rather than assuming a universal hydration volume or mesna percentage.

Methotrexate can cause mucositis, hepatotoxicity, renal-delayed clearance and myelosuppression; MMF can cause gastrointestinal symptoms and cytopenias. Held or modified doses require the transplant prescriber’s protocol decision because omitted prophylaxis may alter GVHD risk.

2. First-Line Treatment and Response Assessment

Before escalating immunosuppression, document organ stage and evaluate competing causes such as infection, medication toxicity, conditioning injury, engraftment syndrome, SOS/VOD, and TA-TMA. Biopsy can support diagnosis when safe, but treatment may begin before pathology in a rapidly progressive presentation.

Limited skin disease may be managed with topical corticosteroids and supportive care. Clinically significant multi-organ, gastrointestinal, hepatic, or extensive skin disease commonly receives systemic corticosteroids; prednisone or methylprednisolone-equivalent dose and route depend on severity and the transplant protocol. Measure rash area, stool volume/frequency and bleeding, bilirubin, nutrition, fluid/electrolyte loss, pain, and performance status consistently.

Response definitions and steroid-refractory/dependent thresholds vary across protocols and trials. Progression within several days, failure to improve after about a week, or inability to taper without recurrence should trigger prompt specialist review rather than an automatic bedside medication change. Document response at the center’s specified milestones.

Systemic corticosteroids and added immunosuppression increase bacterial, viral, fungal, and PJP risk. Select prophylaxis and surveillance from transplant phase, donor/platform, serostatus, steroid exposure, local epidemiology, and current guidance.

3. Steroid-Refractory Acute GVHD and Second-Line Therapy

Progression during an adequate corticosteroid trial, failure to improve at the protocol’s response milestone, inability to taper, or unacceptable toxicity prompts urgent reassessment. Published trials and programs use related but nonidentical day and dose definitions, so classify the patient under the treatment pathway being used. Reconfirm organ stage, adherence and drug exposure; evaluate infection and other mimics; stabilize bleeding, fluid/electrolyte loss and nutrition; and document the same response measures used at baseline.

Ruxolitinib and Other Second-Line Therapy

Ruxolitinib is FDA approved for steroid-refractory acute GVHD in adults and pediatric patients 12 years and older. The current U.S. label starts 5 mg orally twice daily and allows consideration of 10 mg twice daily after at least 3 days if ANC and platelet counts have not decreased by 50% or more relative to the first day of dosing. Dose modification is required for cytopenias, bilirubin changes, renal/hepatic impairment in specified settings, and interacting strong CYP3A4 inhibitors or fluconazole. Monitor CBC with differential, platelets and bilirubin every 2–4 weeks until doses stabilize and as clinically indicated; assess infection risk and follow the current label.

Choice among ruxolitinib, extracorporeal photopheresis, clinical trials, and other organ- or center-specific therapies depends on severity, prior therapy, marrow reserve, infection, organ function, interactions and access. “Steroid refractory” is a prompt for multidisciplinary reassessment, not a single universal drug order.

Other Second-Line & Salvage Modalities

Therapeutic Modality Mechanism of Action Clinical Niche & Nursing Considerations

Extracorporeal photopheresis (ECP) Leukapheresed mononuclear cells are exposed to 8-methoxypsoralen/UVA and reinfused. Used in selected acute-GVHD settings; evidence and organ response vary. Requires reliable access and repeated procedures, and does not eliminate infection or immunosuppression risk from the overall regimen.

Vedolizumab Blocks alpha4beta7-mediated lymphocyte trafficking to the gut. Off-label/investigational for selected steroid-refractory lower-GI disease. Gut selectivity does not mean zero systemic or infectious risk.

Alpha-1 antitrypsin (AAT) Serine-protease inhibitor with anti-inflammatory effects. Investigational; efficacy and infection safety are not established as universally favorable.

Infliximab / etanercept TNF-pathway inhibition. Selected salvage use can add substantial bacterial, fungal and other infection risk; choice requires specialist review.

4. Nursing Management of the Prophylaxis Regimen Itself

Prophylaxis fails as often through administration and monitoring errors as through biology, and each component carries a specific nursing obligation.

Calcineurin inhibitors. Trough levels are meaningful only when drawn immediately before the next scheduled dose; a level drawn at a convenient time is not interpretable and can trigger a wrong dose change. Expect renal impairment and magnesium and potassium wasting, replace aggressively per orders, and report tremor, headache, visual change, hypertension, or seizure promptly because posterior reversible encephalopathy syndrome is a recognized complication. Interactions are extensive, and azole antifungals in particular raise levels substantially.

Methotrexate. Given on defined days after infusion rather than continuously, it worsens mucositis and delays count recovery. Confirm the day is correct against the protocol, since a mistimed dose cannot be undone, and support oral care and pain control aggressively across that window.

Post-transplant cyclophosphamide. Administered on specific early post-infusion days, it requires hydration and mesna for bladder protection and carries cardiac and volume considerations.

Antithymocyte globulin. Expect infusion reactions and cytokine-mediated symptoms; premedication, a graded rate, and immediate availability of rescue medications are the standard of care rather than a precaution for high-risk patients only.